Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + poly-beta-cyclodextrin is a self-assembling inclusion complex formulation designed to overcome the poor aqueous solubility and low bioavailability of curcumin. Curcumin, a natural polyphenol derived from *Curcuma longa*, possesses anti-cancer, anti-oxidant, and anti-inflammatory properties. By complexing curcumin with poly(beta-cyclodextrin), a polymeric form of cyclodextrin, the formulation enhances drug stability and cellular uptake. Research has primarily focused on its potential in treating prostate cancer and colorectal cancer, where it has demonstrated improved therapeutic efficacy in cell lines and safety in early-stage human pilot studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + poly-beta-cyclodextrin.